Tesevatinib

Phase 2Small molecule

KKadmon, a Sanofi Company

Tesevatinib is one of 96 small molecule programs targeting Polycystic Kidney Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Kidney DiseaseActive, not recruiting

Breast CancerActive, not recruiting

GlioblastomaActive, not recruiting

Autosomal Dominant Polycystic Kidney DiseaseActive, not recruiting

Polycystic Kidney DiseasePhase 1

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Autosomal Dominant Polycystic Kidney DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Prolia

Amgen

Preclinical

14 3

Tesevatinib

KKadmon, a Sanofi Company

Phase 2

1 4

MS Contin

Merck & Co.

Preclinical

2 5

Zolymbus

AbbVie

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Tricor

JJagotec

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leptomeningeal Metastases1 trial

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Completed·KKadmon Corporation, LLC·Phase 2·NCT02616393·36 enrolled

Glioblastoma1 trial

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Completed·KKadmon Corporation, LLC·Phase 2·NCT02844439·40 enrolled

Breast Cancer1 trial

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Terminated·KKadmon Corporation, LLC·Phase 1/2·NCT02154529·17 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Completed·KKadmon, a Sanofi Company·Phase 1/2·NCT01559363·69 enrolled

Polycystic Kidney Disease1 trial

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Completed·KKadmon Corporation, LLC·Phase 1·NCT03096080·10 enrolled

2 more indications

Treatment1 trial

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Terminated·KKadmon Corporation, LLC·Phase 2·NCT02616055·15 enrolled

Efficacy and Safety1 trial

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Completed·KKadmon, a Sanofi Company·Phase 2·NCT03203642·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tesevatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tesevatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tesevatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kadmon, a Sanofi Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKadmon, a Sanofi Company

Tesevatinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leptomeningeal Metastases1 trial

Glioblastoma1 trial

Breast Cancer1 trial

Autosomal Dominant Polycystic Kidney Disease1 trial

Polycystic Kidney Disease1 trial

Treatment1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News